Project Grant HT94252410502
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$740K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,200,000.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund Baylor College of Medicine to conduct research on precision glycocalyx editing of the metastatic bone microenvironment over a three-year period from September 15, 2023 to September 14, 2026. As a private non-profit university, Baylor College of Medicine has extensive experience managing federal grants and contracts for biomedical...
The Defense Health Agency awarded a $1,200,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Baylor College of Medicine. The grant, titled "ELIMINATING BONE METASTASIS BY BONE-TARGETING E-CADHERIN ANTIBODY NANOGEL", will fund research to develop an innovative bone-targeting antibody nanogel for the treatment of bone metastasis. The award has a performance period from April 1, 2025 to March 31, 2028. Baylor College of Medicine, a private...
The Baylor College of Medicine was awarded a $1,496,576 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The 4-year grant, with a period of performance from September 1, 2025 to August 31, 2029, will fund research on therapies for classical Ehlers-Danlos syndrome,...
This $1,600,000.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Baylor College of Medicine focused on developing new synthetic lethal combination therapies targeting TopBP1 and the arachidonic acid pathway for breast cancer treatment. The three-year award, with an end date of February 28, 2027, will fund basic, translational, and clinical research aimed at advancing scientific understanding and...
The federal Project Grant award of $1,597,224.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to support the research project "BCL-XL IN BREAST CANCER METASTASIS AND THERAPY" at Baylor College of Medicine in Houston, Texas. The award, with a performance period from August 1, 2024 to July 31, 2027, will fund advanced biomedical research initiatives focused on transforming healthcare for military service...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,759,500.00 to Baylor College of Medicine in Houston, Texas to support research aimed at "Creating Cures for Patients with Langerhans Cell Histiocytosis." The award, which runs from September 1, 2024 to August 31, 2028, will enable Baylor to conduct innovative biomedical studies to develop new treatments and therapies for this rare genetic...
This federal Project Grant award of $802,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical gene therapy studies in a mouse model of TSC2 at Baylor College of Medicine in Houston, TX. The award, effective May 1, 2025 through April 30, 2028, will fund advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The program typically supports a wide range of...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,416,000 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital), a non-profit teaching hospital and research center affiliated with Harvard Medical School. The grant, titled "IND-ENABLING STUDIES OF POLYMERASE INHIBITORS FOR BMF DUE TO TELOMERE EXHAUSTION", will support a 2-year research project from Sep 1, 2023 to Aug 31, 2025. Through this funding, Boston...
Baylor College of Medicine will use a $1.56 million project grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through this four-year award, Baylor College of Medicine will investigate medical solutions for breast cancer through innovative and impactful research aimed at transforming health care for service members and the...
This federal Project Grant award of $2,239,998.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate the progression from ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer driven by the N-RAS gene. The research project aims to advance the understanding of this disease process with the potential to lead to improved diagnostic and treatment approaches. The award...